Welcome to our dedicated page for Iridex news (Ticker: IRIX), a resource for investors and traders seeking the latest updates and insights on Iridex stock.
Iridex Corporation (Nasdaq: IRIX) is a medical device company focused on laser-based ophthalmic systems, and its news flow reflects both commercial performance and clinical adoption of its technology. Company announcements frequently highlight revenue trends, probe and system sales for its Cyclo G6® glaucoma product family, and progress toward goals such as positive adjusted EBITDA and cash flow.
Investors following IRIX news can expect detailed quarterly and preliminary financial updates, including information on total revenue, glaucoma and retina product performance, operating expenses, and non‑GAAP metrics. Iridex also issues releases on matters related to its Nasdaq Capital Market listing status, such as notifications of non‑compliance and subsequent confirmation of regained compliance with stockholders’ equity requirements.
Beyond financial results, Iridex regularly reports on clinical and scientific developments involving its MicroPulse® technology and laser platforms. Recent news has covered independent studies on MicroPulse transscleral laser therapy (MicroPulse TLT) for glaucoma retreatment, thermal modeling comparing MicroPulse and continuous‑wave transscleral cyclophotocoagulation using the Cyclo G6 laser and associated probes, and large investigator‑led trials like DAME and DIAMONDS in diabetic macular edema that use the IQ 577® laser and TxCell® Scanning Delivery Device.
Additional items in the IRIX news stream include participation in investor conferences, webcasts, and other corporate presentations. For market participants, clinicians, and researchers, the Iridex news page offers a centralized view of how the company’s glaucoma and retinal treatment technologies are performing commercially and how they are being evaluated in peer‑reviewed studies and large clinical trials.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Iridex Corporation (Nasdaq: IRIX) reported a 6% increase in full-year revenue to $57 million for 2022, driven by strong sales of its Cyclo G6 glaucoma products. In Q4 2022, total revenue was $15.2 million, with a record 16,400 Cyclo G6 probes sold, up 9% year-over-year. However, retina product revenue declined by 11% to $8.1 million. The company received FDA clearance for new laser systems in late 2022 and early 2023. Despite a net loss of $7.5 million for 2022, with a projected revenue of $57 million to $59 million for 2023, Iridex anticipates growth in Cyclo G6 probe sales between 9% and 12%. Cash reserves stand at $13.9 million.
Iridex Corporation (Nasdaq: IRIX), a leader in ophthalmic laser-based medical products, announced its participation in the 35th Annual Roth Conference in Laguna Niguel, CA. Management will present on March 14, 2023, at 11:00 am PT. Interested individuals can view a live and archived webcast of the presentation on the company's website.
Iridex focuses on innovative treatments for glaucoma and retinal diseases, utilizing its proprietary MicroPulse® technology. The company's products are distributed in over 100 countries, emphasizing their global reach and commitment to addressing serious eye conditions.
Iridex Corporation (NASDAQ: IRIX) announced the publication of Part 2 of the evidence-based guidelines for MicroPulse Transscleral Laser Therapy (TLT) at the 2023 American Glaucoma Society meeting in Austin, Texas. This guide, created by a panel of ten glaucoma experts, covers critical aspects such as anesthesia, surgical technique, and expected outcomes. It builds on Part 1, focusing on dosimetry and patient selection. Attendees can also view Dr. Syril Dorairaj's e-poster on MicroPulse TLT outcomes and demo the Sweep Management Software designed to optimize surgical techniques. Iridex continues to lead in ophthalmic laser-based treatments.
Iridex Corporation (NASDAQ: IRIX) will release its financial results for Q4 and full year 2022 after the market closes on March 9, 2023. The management team will host a conference call at 2:00 PM PT / 5:00 PM ET to discuss the results. Investors can access the live and recorded webcast on the Company’s website. Iridex specializes in innovative ophthalmic laser-based products for treating glaucoma and retinal diseases, utilizing its proprietary MicroPulse® technology. Their products are marketed in the U.S. and over 100 countries worldwide.
Iridex Corporation (Nasdaq: IRIX) announced preliminary financial results for the fourth quarter and full year ended December 31, 2022. Fourth quarter revenue is projected at $15.1 million to $15.3 million, unchanged year-over-year. The company achieved a record sale of 16,400 Cyclo G6 probes, an 8% increase from the previous year. Full year revenue is expected to be between $56.9 million and $57.1 million, reflecting a 6% growth. Cash and equivalents were approximately $13.9 million, with operating cash usage of $1.2 million in Q4.
FAQ
What is the current stock price of Iridex (IRIX)?
What is the market cap of Iridex (IRIX)?
